摘要
目的探究在常规治疗基础上,应用布地奈德、特布他林治疗慢阻肺急性加重期患者的效果。方法选取2021年1月—2023年3月本院收治的89例患者作为研究对象,采用随机数字表法将其分为对照组(44例)和研究组(45例)。方法:对照组接受一般治疗,研究组在对照组基础上,接受布地奈德混悬液联合特布他林治疗。比较两组临床疗效、血常规指标。结果治疗后,研究组临床总有效率较对照组更高;治疗后,两组血清CRP水平、外周血WBC水平均低于治疗前,且研究组低于对照组,两组淋巴细胞百分率均高于治疗前,且研究组高于对照组(P<0.05)。结论慢阻肺急性加重期患者通过布地奈德、特布他林联合治疗,能改善血气指标,疗效更好。
Objective To explore the efficacy of budesonide and terbutaline in the treatment of COPD patients with acute exacerbation on the basis of conventional treatment.Methods A total of 89 patients admitted from January 2021 to March 2023 were selected as study objects and divided into control group(44 cases)and study group(45 cases)by random number table method.Methods:The control group received general treatment,and the study group received budesonide suspension combined with terbutaline on the basis of the control group.The clinical efficacy and blood routine indexes of the two groups were compared.Results After treatment,the total effective rate of the study group was higher than that of the control group.After treatment,serum CRP level and peripheral blood WBC level in both groups were lower than before treatment,and the study group was lower than the control group,and the percentage of lymphocyte in both groups was higher than before treatment,and the study group was higher than the control group(P<0.05).Conclusion The combination therapy of budesonide and terbutaline can improve blood gas index in patients with acute COPD exacerbation,and the curative effect is better.
作者
任仕斌
REN Shibin(Wuzhong City Yanchi County Traditional Chinese Medicine Hospital,Ningxia Hui Autonomous Region,Wuzhong,Ningxia 751500)
出处
《智慧健康》
2024年第24期60-62,共3页
Smart Healthcare
关键词
急性加重期
慢阻肺
布地奈德
特布他林
血常规
Acute exacerbation
Copd
Budesonide
Terbutaline
Blood routine examination
